These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18455194)

  • 1. The use of diversity profiling to characterize chemical modulators of the histone deacetylases.
    Blackwell L; Norris J; Suto CM; Janzen WP
    Life Sci; 2008 May; 82(21-22):1050-8. PubMed ID: 18455194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F; Mercurio C
    ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors.
    Liao D
    Drug Discov Today Technol; 2015 Nov; 18():24-8. PubMed ID: 26723889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
    Henkes LM; Haus P; Jäger F; Ludwig J; Meyer-Almes FJ
    Bioorg Med Chem; 2012 Jan; 20(2):985-95. PubMed ID: 22182579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
    Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
    Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-specific histone deacetylase inhibitors: the next step?
    Balasubramanian S; Verner E; Buggy JJ
    Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylases: structural determinants of inhibitor selectivity.
    Micelli C; Rastelli G
    Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW
    Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
    Carrillo AK; Guiguemde WA; Guy RK
    Bioorg Med Chem; 2015 Aug; 23(16):5151-5. PubMed ID: 25637120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
    Minucci S; Pelicci PG
    Nat Rev Cancer; 2006 Jan; 6(1):38-51. PubMed ID: 16397526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.
    Stolfa DA; Stefanachi A; Gajer JM; Nebbioso A; Altucci L; Cellamare S; Jung M; Carotti A
    ChemMedChem; 2012 Jul; 7(7):1256-66. PubMed ID: 22628266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Giannini G; Cabri W; Fattorusso C; Rodriquez M
    Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
    Ganai SA; Shanmugam K; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.